The paper from Fu et al. reported a novel PEGylated nanoliposomal formulation that co-delivers a protein kinase C inhibitor and a BRD4 PROTAC, ARV-825, to address vemurafenib-resistant melanoma [106]. This evidence concerns the gene BRD4 and melanoma.